Cold Spring Harbor, NY – September 15, 2022 – Cold Spring Harbor Laboratory Press (CSHL Press), a publisher of scientific books, journals, and electronic media, today announced a new initiative to broaden access to the expanding science of glycobiology. Supported by an unconditional grant from InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, the e-book of Essentials of Glycobiology (4th Edition) published by CSHL Press is being made available to readers free of charge, ensuring equitable access for all biologists and translational researchers throughout the world.
Essentials of Glycobiology has become the gold standard textbook and key reference work in this field over the past 20 years. The 4th edition of the book, which was thoroughly revised earlier this year, has an expanded international editorial board and a diverse panel of contributing authors, representing a wide range of expertise in emerging areas.
Other key enhancements include a broadened focus on all lineages of life-forms in nature, increased coverage of topics, and in-depth attention to informatics and the exploration of the glycome and the glycoproteome. Most of the figures—many featuring artwork by one of the book’s editors, Richard Cummings of Harvard University—are also downloadable for nonprofit and teaching purposes.
“The editors of the book are very pleased about the opportunity provided to make the text available as an e-book to all interested audiences,” said Dr. Ajit Varki, Distinguished Professor, University of California at San Diego, and Executive Editor of the textbook. “Awareness of the importance of glycobiology and glycoscience among a range of life science and biomedical constituencies still has a long way to go, and free access for all to the e-book represents an important step in raising visibility for the discipline, building on the editors’ long-standing commitment to open access via the NCBI/NLM Bookshelf.”
“We are grateful to InterVenn for the support that allowed the distribution of Essentials of Glycobiology as a free, fully featured, downloadable e-book” said Dr. John Inglis, Executive Director at CSHL Press. “This initiative increases the diversity of this valuable content’s availability and aligns with the open science goals of CSHL Press.”
“InterVenn is privileged to be able to contribute to this important scientific and educational effort by making the world’s leading textbook of the discipline of glycobiology freely available to all as an e-book,” said Dr. Klaus Lindpaintner, InterVenn Distinguished Scientist and CSO. “As a company pioneering the translation of glycobiology and glycoproteomics into the clinic, we are acutely aware of the need for more visibility and understanding of the field, particularly given the mounting evidence for the ubiquitous impact glycosylation has in health and disease. We thank the book’s Consortium of Glycobiology Editors, as well as the team at CSHL, for this opportunity.”
The e-book version of Essentials of Glycobiology can be accessed at www.cshlpress.org/glycobiology.
About Cold Spring Harbor Laboratory Press
Cold Spring Harbor Laboratory Press is an internationally renowned not-for-profit publisher of books, journals, and electronic media, located on Long Island, New York. Since 1933, it has furthered the advance and spread of scientific knowledge in all areas of genetics and molecular biology, including cancer biology, plant science, bioinformatics, and neurobiology. It is a division of Cold Spring Harbor Laboratory, an innovator in life science research and the education of scientists, students, and the public. All revenue from sales of CSHL Press publications supports research at Cold Spring Harbor Laboratory.
About InterVenn Biosciences
InterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode and unlock the potential of the glycoproteome at clinically meaningful scale for the first time in history. To optimize this entirely new dimension of biology, the company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.